ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) reported the repurchase of 63,800 H shares on 17 July 2026. The buyback, executed on the Hong Kong Stock Exchange, was completed at prices ranging between HKD 3.39 and HKD 3.59 per share, with a volume-weighted average of HKD 3.45. Total consideration amounted to HKD 0.22 million.

Prior to the transaction, the company had 418.69 million issued shares (excluding treasury shares) and 1.79 million treasury shares. Following the repurchase, issued shares outstanding fell by 0.0152 % to 418.63 million, while treasury shares rose to 1.85 million. The total issued share capital remained unchanged at 420.48 million shares, as the repurchased stock is being held in treasury and has not been cancelled.

The buyback forms part of the mandate granted by shareholders on 28 May 2026, which authorises the company to repurchase up to 43.15 million shares. Cumulative repurchases under this mandate now stand at 1.85 million shares, equivalent to 0.43 % of the company’s issued share capital on the mandate date. Pursuant to Hong Kong listing rules, ImmuneOnco is subject to a moratorium on issuing new shares or disposing of treasury shares until 17 August 2026.